Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
DE0006632003
Fri, 07.01.2022
MorphoSys AG
Publication of an inside information according to Article 17 para. 1 of the Regulation (EU) No. 596/2014
Planegg/Munich, Germany, January 07, 2022
Ad hoc: MorphoSys AG Reports Preliminary 2021 Monjuvi U.S. Sales and Provides 2022 Financial Guidance
- Preliminary 2021 Monjuvi U.S. net product sales of US$ 79.1 million (€ 66.9 million)
- Antici [ … ]
Sun, 12.12.2021
MorphoSys AG
MorphoSys presents latest data from the Phase 2 MANIFEST Study evaluating the potential of pelabresib in the treatment of myelofibrosis
Data presented during poster and oral sessions at the 63rd American Society of Hematology Annual Meeting and Exposition
Latest results from the MANIFEST trial underscore the rationale to further explore pelabres [ … ]
Sat, 11.12.2021
MorphoSys AG
MorphoSys and Incyte Announce Additional Real-World Evidence Results from RE-MIND2 Study of Tafasitamab (Monjuvi(R)) in Combination with Lenalidomide for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- RE-MIND2 compared patient outcomes from pivotal L-MIND study with matched patient populations treated with NCCN/ESMO recomm [ … ]
Mon, 29.11.2021
MorphoSys AG
Media Release
Planegg/Munich, Germany, November 29, 2021
MorphoSys AG: Corporate Calendar 2022
Dear Madam/Sir,
Please note MorphoSys' financial reporting dates 2022 as follows:
Publication of Interim Statement / Report
Conference Call
Year-End Results 2021
March 16, 2022 // 10 pm CET
(5 pm EDT; 9 pm GMT)
March 17, 2022 // [ … ]
Wed, 10.11.2021
MorphoSys AG
MorphoSys AG Reports First Nine Months and Third Quarter 2021 Results- Monjuvi U.S. net product sales of US$ 22.0 million (€ 18.6 million), 22% growth Q-Q
- Ten abstracts, including two oral presentations, accepted at upcoming ASH
- Pelabresib data for arm 3 of MANIFEST study to be presented at ASH confirm prior data
- Felzartamab demonstrated proo [ … ]
Tue, 09.11.2021
MorphoSys AG
Media Release
MorphoSys Announces Departure of Roland Wandeler
Planegg/Munich, Germany, November 9, 2021 - MorphoSys AG (FSE: MOR; NASDAQ: MOR) announced today that Roland Wandeler, Ph.D., has decided to step down from his position as Chief Operating Officer (COO) and member of the MorphoSys Management Board effective December 31, 2021 to pursu [ … ]
Thu, 04.11.2021
MorphoSys AG
MorphoSys presents interim results from M-PLACE study with felzartamab during American Society of Nephrology Annual MeetingFelzartamab has the potential to rapidly and substantially reduce anti-PLA2R antibody titers in patients with anti-PLA2R-positive membranous nephropathy
MorphoSys AG (FSE: MOR; NASDAQ: MOR) presented interim results from the M- [ … ]
Thu, 04.11.2021
MorphoSys AG
MEDIA RELEASE
MorphoSys to present MANIFEST and RE-MIND2 data from expanded hematology-oncology portfolio at the 2021 American Society of Hematology (ASH) Annual Meeting- Updates from MANIFEST phase 2 trial in patients with myelofibrosis, including clinical updates on JAK naïve patients treated with pelabresib in combination with ruxolitinib, incl [ … ]
Tue, 02.11.2021
MorphoSys AG
Media Release
Planegg/Munich, Germany, November 02, 2021
MorphoSys AG announces Monjuvi(R) Sales for the First Nine Months and Third Quarter of 2021 and Invitation to the upcoming Conference Call on November 11, 2021
MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announces that revenues from product sales of Monjuvi(R) (tafasitamab-cxix) in the U.S. [ … ]
Wed, 20.10.2021
MorphoSys AG
First Patient Dosed in Phase 2 IGNAZ Study of Felzartamab in Patients with Immunoglobulin A Nephropathy
MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announced that the first patient has been dosed in the Phase 2 IGNAZ clinical trial evaluating felzartamab for patients with Immunoglobulin A Nephropathy (IgAN). IgAN, also known as Berger's disease, is [ … ]